LDLR-Negative Packaging Cell Line for VSV-G Vector Production

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current protocols for producing VSV-G pseudotyped retroviral vector particles face challenges such as low reproducibility, cytotoxicity, and high autotransduction rates in packaging cell lines, which limit yield and stability.

Innovation Solution

The use of packaging cell lines that are negative for the Low-Density Lipoprotein Receptor (LDLR) addresses these issues by reducing autotransduction, increasing yield, and minimizing cytotoxicity associated with VSV-G expression.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If packaging cell lines express LDLR on their surface, then VSV-G pseudotyped retroviral vector particles can be produced, but autotransduction rates increase and yield decreases

Engineering Contradiction:

Improveyield of VSV-G pseudotyped retroviral vector particlesVSAvoidautotransduction rates

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent removes the LDLR receptor from the packaging cell line surface through genetic modification (knockout), extracting the harmful element that causes autotransduction while preserving the cell's ability to produce VSV-G pseudotyped retroviral vector particles. This resolves the contradiction by eliminating the receptor that would otherwise mediate autotransduction and reduce yield.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent changes the expression status of the LDLR parameter from present to absent in the packaging cell line. This parameter change fundamentally alters the interaction between the packaging cells and the produced viral particles, preventing autotransduction while maintaining production capability, thus resolving the yield-reliability contradiction.

Inventive Principle:

Principle #35Parameter changes

2Adaptability or versatility

If transient protocols are used with plasmid transfection, then flexibility is achieved, but reproducibility of yield decreases

Engineering Contradiction:

Improveflexibility in exchanging plasmidsVSAvoidreproducibility of yield

Core Design Contradiction:

Adaptability or versatilityVSManufacturing precision

Solution Approach 1:

The patent creates packaging cell lines that stably express VSV-G and other necessary components, allowing the cells to self-sustain the production of VSV-G pseudotyped retroviral vector particles without requiring repeated plasmid transfection. This stable expression system provides both flexibility for different applications and high reproducibility for yield, resolving the contradiction between adaptability and manufacturing precision.

Inventive Principle:

Principle #25Self-service

3Reliability

If VSV-G is continuously expressed in packaging cells, then stable production is achieved, but cytotoxicity increases

Engineering Contradiction:

Improvestability of productionVSAvoidcytotoxicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent employs inducible expression systems that allow dynamic control of VSV-G expression. The system can be activated during the production phase to achieve stable production and then deactivated to reduce cytotoxicity, enabling both stable production and reduced harmful effects through temporal dynamics of gene expression.

Inventive Principle:

Principle #15Dynamics

Data Source

PatentUS12286639B2LDLR negative packaging cell line for the production of VSV-G pseudotyped retroviral vector particles or virus particles thereof

Publication Date: 2025.04.29 MILTENYI BIOTEC BV & CO KG

AI summary

The present invention provides the use of a packaging cell line for the production of VSV-G pseudotyped retroviral vector particles or virus like particles thereof, wherein said packaging cell line is negative for Low-Density Lipoprotein Receptor (LDLR), optionally said packaging cell line stably expresses VSV-G. A method for producing said VSV-G pseudotyped retroviral vector particles or virus like particles thereof is disclosed as well as said particles obtained by said method.